Schizophrenia/Psychosis

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

New analysis reveals that negative symptoms and stimulant use may predict positive responses to Cobenfy in schizophrenia treatment.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Halloween poses unique challenges for individuals with mental health disorders, but strategies exist to help them navigate the spooky season safely.

In this CME article, explore the complexities of diagnosing and managing catatonia in patients with overlapping neuropsychiatric conditions.

Laguna Diagnostics revolutionizes psychiatric interventions with patented blood tests that accurately diagnose schizophrenia and bipolar disorder.

Semaglutide shows promise in enhancing cognitive function for individuals with psychiatric disorders, particularly improving memory and overall cognitive outcomes.

Explore the intersection of synchronicity and psychiatry, revealing how meaningful coincidences can enhance understanding and healing in mental health.

A recent study reveals that the choice of initial antipsychotic significantly impacts long-term weight gain, highlighting the complexity of treatment outcomes.

A recent study highlights lumateperone's effectiveness in preventing schizophrenia relapse, showcasing its potential for long-term treatment benefits.

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

This infographic can help you review 6 highlights from the INTEGRATE Guidelines.

Explore the evolving landscape of psychiatric diagnosis and treatment, highlighting the gap between evidence-based standards and real-world practices.

International guidelines for schizophrenia treatment standardize care, addressing disparities and emphasizing proactive metabolic management for better patient outcomes.

Alto Neuroscience's ALTO-101 gains FDA fast track designation, promising a novel treatment for cognitive impairment in schizophrenia.

In this CME article, explore the complexities of movement disorders in psychiatric practice, including their causes, symptoms, and treatment strategies for better patient care.

A new study reveals the overwhelming financial and emotional burdens faced by caregivers of individuals with schizophrenia, highlighting urgent support needs.

New research highlights the effectiveness of early psychosis intervention programs, emphasizing low caseloads and clozapine access to reduce relapse rates.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.

Exploring the prevalence and implications of psychotropic polypharmacy in patients taking clozapine with treatment-resistant schizophrenia.